The story of the erectile dysfunction drug presents a complex picture for investors. While the initial launch generated massive gains, the lapse of its exclusive rights opened the floodgates to cheaper competitors, dramatically eroding revenue. This poses a unique challenge for firms depending on similar blockbuster medications, suggesting that a u

The history of Viagra, and its creator copyright, presents a challenging case study for investors. At first a blockbuster drug, yielding billions in revenue , its patent expiration created a wave of generic competition , significantly impacting its market share . While specific businesses may attempt to capitalize on male sexual dysfunction, the cu